drugset / Trial / NCT02643082

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

NCT02643082

Phase 3 Completed 20 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance With Moderate to Severe COPD.

Timeline

Start
2015-12-23
Primary completion
2017-01-26
Completion
2017-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 9.6 ug Inhaled
Subject Glycopyrronium Unknown 14.4 ug Inhaled